"But wait there's more." Continuing the saga of ho

"But wait there's more." Continuing the saga of how the global reach of Big Pharma has impeded Novavax (and, in my opinion, CYDY), THIS is what caused a 30% sell-off in NVAX today, the day it should have been up hugely on news that the FDA had finally, reluctantly, 7 months after data submission, agreed to approve the vaccine, as the Advisory Committee did UNANIMOUSLY almost 10 days ago:

Two. Two cases of severe allergic reaction, in a vaccine that has been approved in 41 countries.

We've heard about MANY more cases of allergic reactions in the Pfizer and Moderna vaccines, yet THEIR stocks didn't magically get a scary press release talking about allergic reactions on the first trading day after they were approved.

Think that the FDA is neutral and scientific? Please allow me to present you with the keys to Fort Knox, for a small million-dollar fee.

Quote:

---

Novavax Statement on European Medicines Agency Nuvaxovid™ Label Update Related to Allergic Reaction

Today, the European Medicines Agency (EMA) updated the label for our COVID-19 vaccine (NVX-CoV2373) to include the risk of severe allergic reactions. This update is a warning commonly included for commercially available vaccines, including COVID-19 vaccines. Novavax’ clinical development program reported no severe allergic reactions and therefore, this risk was not listed in the initial product label.

With broader deployment of doses, we have received reports of two cases of anaphylaxis (allergic reaction) that met a probable/definite case definition. Because anaphylaxis can occur with all vaccines and based on these cases, Novavax and the EMA agreed to update the label accordingly. We will continue to monitor all adverse events, including allergic reactions.

Authorization in the U.S.

The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration.

---